{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:50:30Z","timestamp":1779162630704,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s13760-018-0943-7","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T05:53:15Z","timestamp":1527832395000},"page":"435-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antibody profile may predict outcome in ocular myasthenia gravis"],"prefix":"10.1007","volume":"118","author":[{"given":"Giuliana","family":"Galassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ariatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaniko","family":"Kaleci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Valzania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo F.","family":"Nichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","volume":"357","author":"A Vincent","year":"2001","unstructured":"Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357:2122\u20132128. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(00)05186-2","journal-title":"Lancet"},{"key":"943_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475\u2013490. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(09)70063-8","journal-title":"Lancet Neurol"},{"key":"943_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48\u201349","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48\u201349:143\u2013148. \n                    https:\/\/doi.org\/10.1016\/j.jaut.2014.01.00352\n                    \n                   139\u2013145","journal-title":"J Autoimmun"},{"issue":"6","key":"943_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/ICU.0b013e328358b94a","volume":"23","author":"MS Vaphiades","year":"2012","unstructured":"Vaphiades MS, Bhatti MT, Lesser RL (2012) Ocular myasthenia gravis. Curr Opin Ophthalmol 23(6):537\u2013542. \n                    https:\/\/doi.org\/10.1097\/ICU.0b013e328358b94a","journal-title":"Curr Opin Ophthalmol"},{"key":"943_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 16:459\u2013467. \n                    https:\/\/doi.org\/10.1016\/j.nmd.2006.05.006","journal-title":"Neuromuscul Disord"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archneur.60.2.243","volume":"60","author":"MJ Kupersmith","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P (2003) Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 60:243\u2013248. \n                    https:\/\/doi.org\/10.1001\/archneur.60.2.243","journal-title":"Arch Neurol"},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/00207454.2013.853664","volume":"124","author":"A Ariatti","year":"2014","unstructured":"Ariatti A, Stefani M, Miceli P, Benuzzi F, Galassi G (2014) Prognostic factors and health-related quality of life in ocular myasthenia gravis (OMG). Int J Neurosci 124:427\u2013435. \n                    https:\/\/doi.org\/10.3109\/00207454.2013.853664","journal-title":"Int J Neurosci"},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.23236","volume":"45","author":"HD Katzberg","year":"2012","unstructured":"Katzberg HD, Barnett C, Bril V (2012) Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve 45:648\u2013652. \n                    https:\/\/doi.org\/10.1002\/mus.23236","journal-title":"Muscle Nerve"},{"issue":"2","key":"943_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149. \n                    https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","volume":"72","author":"CE Peeler","year":"2015","unstructured":"Peeler CE, De Lott LB, Nagia L, Lemos J, Eggenberger ER, Cornblath WT (2015) Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol 72:1170\u20131174. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2015.1444","journal-title":"JAMA Neurol"},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological Societies (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893\u2013902. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03019.x","journal-title":"Eur J Neurol"},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","volume":"71","author":"MJ Bhanushali","year":"2008","unstructured":"Bhanushali MJ, Wuu J, Benatar M (2008) Treatment of ocular symptoms in myasthenia gravis. Neurology 71:1335\u20131341. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000327669.75695.38","journal-title":"Neurology"},{"key":"943_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00415-010-5746-6","volume":"258","author":"Z Argov","year":"2011","unstructured":"Argov Z (2011) Current approach to seronegative myasthenia. J Neurol 258:14\u201318. \n                    https:\/\/doi.org\/10.1007\/s00415-010-5746-6","journal-title":"J Neurol"},{"key":"943_CR14","first-page":"933","volume":"51","author":"JM Lindstrom","year":"1998","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1998) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 51:933\u2013933","journal-title":"Neurology"},{"key":"943_CR15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, Gomez AM, De Baets MH, Losen M (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase, and low-density lipoprotein receptor-related protein 4. Autoimmune Rev 12:918\u2013923. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001","journal-title":"Autoimmune Rev"},{"key":"943_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","volume":"53","author":"M Benatar","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R, Muscle Study Group (MSG) (2016) Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve 53:363\u2013369. \n                    https:\/\/doi.org\/10.1002\/mus.24769","journal-title":"Muscle Nerve"},{"key":"943_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/WNO.0000000000000270","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Plant GT, Cornblath W (2016) Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol 36:98\u2013102. \n                    https:\/\/doi.org\/10.1097\/WNO.0000000000000270","journal-title":"J Neuroophthalmol"},{"key":"943_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep 14:421. \n                    https:\/\/doi.org\/10.1007\/s11910-013-0421-9","journal-title":"Curr Neurol Neurosci Rep"},{"key":"943_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. \n                    https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"issue":"3","key":"943_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/mus.21555","volume":"41","author":"JA Allen","year":"2010","unstructured":"Allen JA, Scala S, Jones HR (2010) Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 41(3):379\u2013384. \n                    https:\/\/doi.org\/10.1002\/mus.21555","journal-title":"Muscle Nerve"},{"key":"943_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2017.07.006","volume":"49","author":"F Romi","year":"2017","unstructured":"Romi F, Hong Y, Gilhus NE (2017) Pathophysiology and immunological profile of myasthenia gravis and its subgroups. Curr Opin Immunol 49:9\u201313. \n                    https:\/\/doi.org\/10.1016\/j.coi.2017.07.006","journal-title":"Curr Opin Immunol"},{"key":"943_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268. \n                    https:\/\/doi.org\/10.1038\/nrneurol.2016.44","journal-title":"Nat Rev Neurol"},{"key":"943_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Petrie A, Plant GT (2016) Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 36:252\u2013258. \n                    https:\/\/doi.org\/10.1097\/WNO.0000000000000350","journal-title":"J Neuroophthalmol"},{"key":"943_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jocn.2005.04.028","volume":"13","author":"JY Lee","year":"2006","unstructured":"Lee JY, Sung JJ, Cho JY, Oh DH, Kim HJ, Park JH, Lee KW, Choi YC, Vincent A (2006) MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci 13:353\u2013355. \n                    https:\/\/doi.org\/10.1016\/j.jocn.2005.04.028","journal-title":"J Clin Neurosci"},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/jnnp-2017-315782","volume":"88","author":"A Evoli","year":"2017","unstructured":"Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E (2017) Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry 88:761\u2013763. \n                    https:\/\/doi.org\/10.1136\/jnnp-2017-315782","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"943_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44:36\u201340. \n                    https:\/\/doi.org\/10.1002\/mus.22006","journal-title":"Muscle Nerve"},{"key":"943_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","volume":"284","author":"AI Tsonis","year":"2015","unstructured":"Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba- Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakub\u0131\u00b4kova M, Hanisch F, Tzartos SJ (2015) MuSK autoantibodies in myasthenia gravis detected by cell-based assay: a multinational study. J Neuroimmunol 284:10\u201317. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2015.04.015","journal-title":"J Neuroimmunol"},{"key":"943_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21:687\u2013693. \n                    https:\/\/doi.org\/10.1111\/ene.12359","journal-title":"Eur J Neurol"},{"issue":"1","key":"943_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki 3rd A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16\u201323","journal-title":"Neurology"},{"key":"943_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","volume":"128","author":"M Mazzoli","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G (2018) Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci 128:15\u201324. \n                    https:\/\/doi.org\/10.1080\/00207454.2017.1344237","journal-title":"Int J Neurosci"},{"key":"943_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/ene.12057","volume":"20","author":"H Zach","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, Paul A, Wuschitz B, Jung R, Auff E, Zimprich F (2013) The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol 20:708\u2013713. \n                    https:\/\/doi.org\/10.1111\/ene.12057","journal-title":"Eur J Neurol"},{"key":"943_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/01.cnd.0000155026.66153.f0","volume":"6","author":"HD Katzberg","year":"2005","unstructured":"Katzberg HD, Bril V (2005) A comparison of electrodiagnostic tests in ocular myasthenia gravis. J Clin Neuromuscul Dis 6:109\u2013113. \n                    https:\/\/doi.org\/10.1097\/01.cnd.0000155026.66153.f0","journal-title":"J Clin Neuromuscul Dis"},{"key":"943_CR33","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/(SICI)1097-4598(199909)22:9<1222::AID-MUS8>3.0.CO;2-R","volume":"22","author":"DH Weinberg","year":"1999","unstructured":"Weinberg DH, Rizzo 3rd JF, Hayes MT, Kneeland MD, Kelly Jr JJ (1999) Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 22:1222\u20131227","journal-title":"Muscle Nerve"},{"key":"943_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/mus.21853","volume":"43","author":"R Mercelis","year":"2011","unstructured":"Mercelis R, Merckaert V (2011) Diagnostic utility of stimulated single-fiber electromyography of the orbicularis oculi muscle in patients with suspected ocular myasthenia. Muscle Nerve 43:168\u2013170. \n                    https:\/\/doi.org\/10.1002\/mus.21853","journal-title":"Muscle Nerve"},{"key":"943_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/mus.25174","volume":"54","author":"M Baruca","year":"2016","unstructured":"Baruca M, Leonardis L, Podnar S, Hojis-Fabian T, Grad A, Jerin SA, Blagus R, Sega-Jazbec S (2016) Single fiber EMG as prognostic tool in myasthenia gravis. Muscle Nerve 54:1034\u20131040. \n                    https:\/\/doi.org\/10.1002\/mus.25174","journal-title":"Muscle Nerve"},{"key":"943_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM, Marino M, Ciaraffa F, Evoli A (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67:505\u2013507. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000228225.23349.5d","journal-title":"Neurology"},{"key":"943_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","volume":"68","author":"F Deymeer","year":"2007","unstructured":"Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, Vincent A, Saruhan-Direskeneli G (2007) Clinical comparison of anti-MuSK vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68:609\u2013611. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000254620.45529.97","journal-title":"Neurology"},{"key":"943_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/bjo.2006.108498","volume":"91","author":"JW Chan","year":"2007","unstructured":"Chan JW, Orrison WW (2007) Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophy. Br J Ophthalmol 91:842\u2013843. \n                    https:\/\/doi.org\/10.1136\/bjo.2006.108498","journal-title":"Br J Ophthalmol"},{"key":"943_CR39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-005-0032-8","volume":"253","author":"F Hanisch","year":"2006","unstructured":"Hanisch F, Eger K, Zierz S (2006) MuSK-antibody positive pure ocular myasthenia gravis. J Neurol 253:659\u2013660. \n                    https:\/\/doi.org\/10.1007\/s00415-005-0032-8","journal-title":"J Neurol"},{"key":"943_CR40","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneur.62.6.1002","volume":"62","author":"JB Caress","year":"2005","unstructured":"Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62:1002\u20131003. \n                    https:\/\/doi.org\/10.1001\/archneur.62.6.1002","journal-title":"Arch Neurol"},{"key":"943_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jns.2013.05.001","volume":"331","author":"V Zouvelou","year":"2013","unstructured":"Zouvelou V, Stamboulis E, Skriapa L, Tzartos SJ (2013) MuSK-Ab positive myasthenia: not always grave. J Neurol Sci 331:150\u2013151. \n                    https:\/\/doi.org\/10.1016\/j.jns.2013.05.001","journal-title":"J Neurol Sci"},{"key":"943_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s13760-015-0460-x","volume":"115","author":"T Zambelis","year":"2015","unstructured":"Zambelis T, Pappas V, Kokotis P, Zouvelou V, Karandreas N (2015) Patients with ocular symptoms referred for electrodiagnosis: how many of them suffer from myasthenia gravis? Acta Neurol Belg 115:671\u2013674. \n                    https:\/\/doi.org\/10.1007\/s13760-015-0460-x","journal-title":"Acta Neurol Belg"},{"key":"943_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418\u2013422. \n                    https:\/\/doi.org\/10.1002\/ana.22312","journal-title":"Ann Neurol"},{"key":"943_CR44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","volume":"24","author":"Y Hong","year":"2017","unstructured":"Hong Y, Zisimopoulou P, Trakas N, Karagiorgou K, Stergiou C, Skeie GO, Hao HL, Gao X, Owe JF, Zhang X, Yue YX, Romi F, Wang Q, Li HF, Gilhus NE, Tzartos SJ (2017) Multiple antibody detection in \u201cseronegative\u201d myasthenia gravis patients. Eur J Neurol 24:844\u2013850. \n                    https:\/\/doi.org\/10.1111\/ene.13300","journal-title":"Eur J Neurol"},{"key":"943_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","volume":"1412","author":"I Illa","year":"2018","unstructured":"Illa I, Cort\u00e9s-Vicente E, Mart\u00ednez M, Gallardo E (2018) Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci 1412:90\u201394. \n                    https:\/\/doi.org\/10.1111\/nyas.13502","journal-title":"Ann N Y Acad Sci"},{"key":"943_CR46","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","volume":"291","author":"MG Huijbers","year":"2016","unstructured":"Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-Garc\u00eda R, D\u00edaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ (2016) Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol 291:82\u201388. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2015.12.016","journal-title":"J Neuroimmunol"},{"key":"943_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","volume":"325","author":"MA Hellmann","year":"2013","unstructured":"Hellmann MA, Mosberg-Galili R, Steiner I (2013) Myasthenia gravis in the elderly. J Neurol Sci 325:1\u20135. \n                    https:\/\/doi.org\/10.1016\/j.jns.2012.10.028","journal-title":"J Neurol Sci"},{"key":"943_CR48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mus.23964","volume":"48","author":"NM Alkhawajah","year":"2013","unstructured":"Alkhawajah NM, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve 48:705\u2013710. \n                    https:\/\/doi.org\/10.1002\/mus.23964","journal-title":"Muscle Nerve"},{"key":"943_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000487132","volume":"79","author":"F Aguirre","year":"2018","unstructured":"Aguirre F, Villa AM (2018) Prognosis of ocular myasthenia gravis in an Argentinian population. Eur Neurol 79:113\u2013117. \n                    https:\/\/doi.org\/10.1159\/000487132","journal-title":"Eur Neurol"},{"key":"943_CR50","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mus.25205","volume":"54","author":"JB Andersen","year":"2016","unstructured":"Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54:1041\u20131049. \n                    https:\/\/doi.org\/10.1002\/mus.25205","journal-title":"Muscle Nerve"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-018-0943-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-018-0943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-018-0943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T06:43:56Z","timestamp":1559371436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-018-0943-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s13760-018-0943-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,1]]},"assertion":[{"value":"5 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. All the procedures were accordance with the ethical standard of yhe Instutional\/ and\/or national research committee and with the 1964 Helsinki declaration and its later amendements or comparable ethical standards. The original study on Myasthenia gravis was approved by Institutional University Hospital Ethic Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"For this type of study formal informed consent is not required","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}